FDA OKs clinical testing of VS-7375 for pancreatic cancer tumors

FDA OKs clinical testing of VS-7375 for pancreatic cancer tumors

The U.S. Food and Drug Administration (FDA) has given Verastem Oncology the green light to start clinical testing of its oral treatment candidate VS-7375 in people with advanced solid tumors — such as colorectal, non-small cell lung, and pancreatic cancers — that are positive for the G12D mutation in the KRAS gene. Verastem now plans to launch a Phase 1/2 trial in the U.S. by about mid-year, with the potential to later expand globally, according…